Sarepta Therapeutics Stock Emerges as Long Build Up Play With Elevidys' Three-Year DMD Success

Sarepta Therapeutics’ [SRPT] recent clinical milestone could be reshaping the narrative around this biotech stock as a potential long build up opportunity for patient investors. The company announced positive three-year data from its Phase III EMBARK study evaluating Elevidys in ambulatory patients with Duchenne muscular dystrophy (DMD) aged 4 to 7 at initial dosing. This breakthrough, combined with the company’s ongoing recovery from past regulatory headwinds, suggests why some investors view SRPT as a stocks worth accumulating through strategic rallies.

The market initially responded with enthusiasm—SRPT shares jumped approximately 8% following the data release on Monday. However, context matters: the stock has declined 80.5% over the past year against an industry that rose 17.2%, highlighting just how deep the pullback has been. For long build up focused investors, such washouts often precede meaningful recovery phases when fundamentals improve.

Three-Year Clinical Breakthrough: How Elevidys Is Building Long-Term Value

The Phase III EMBARK study’s Part 1 data demonstrated what clinical success looks like in a historically challenging indication. Approximately 52 patients treated with Elevidys maintained significantly higher motor function three years after infusion, with North Star Ambulatory Assessment (NSAA) scores remaining above baseline levels. This stood in stark contrast to an external control group of untreated patients, which exhibited the typical age-related decline expected in DMD progression.

The magnitude of improvement was substantial. Elevidys slowed disease progression by 73% as measured by time to rise (TTR)—the speed at which patients can stand from the floor—and by 70% as measured by 10-meter walk run (10MWR). For a rare genetic disease where progression is typically relentless, a 70-73% deceleration represents a genuinely meaningful clinical benefit. Critically, no new safety signals emerged during the three-year follow-up period. At their most recent assessment, patients had a mean age of nine years, a developmental stage where DMD typically accelerates functional decline.

This long-term data reinforces why Elevidys holds potential as a cornerstone therapy. For a biotech company rebuilding investor confidence, such durable clinical proof points are essential building blocks.

Navigating the Path Forward: Elevidys’ Regulatory Journey and Commercial Implications

Elevidys’ path has been anything but smooth, which is precisely why understanding the opportunity matters for long build up investors. The therapy received FDA approval in June 2023 as the first and only gene therapy for DMD, positioning Sarepta in a monopoly position within this indication. Roche secured international marketing rights, expanding the commercial footprint beyond the U.S.

However, tragedy disrupted that momentum. In 2025, after two non-ambulatory boys with DMD died of acute liver failure following Elevidys treatment, Sarepta voluntarily paused shipments to non-ambulatory patients. The FDA responded with significant label modifications: restricting use to ambulatory patients only, adding boxed warnings for severe liver risks, and implementing stricter monitoring requirements for liver impairment, recent vaccinations, and infections.

These restrictions had immediate commercial consequences. In Q3 2025, Elevidys generated $131.5 million in revenue—a substantial decline from $181 million in the same quarter of 2024. Lower volumes directly resulted from the non-ambulatory patient suspension and associated caution among prescribers. For investors tracking this stock’s recovery narrative, this represents a critical inflection point: the positive three-year ambulatory data now provides evidence that the narrowed indication still maintains robust efficacy. This could help restore physician and patient confidence, potentially reigniting sales growth in future periods.

Why Sarepta Stock Could Build Strength for Patient Long-Term Investors

From an investment standpoint, Sarepta presents a textbook scenario for long build up strategies: a company with a monopoly therapy, solid clinical proof, but a stock hammered by regulatory complications and safety concerns. The Phase III data essentially validates the path forward—Elevidys works durably in its approved population.

Several factors could support a gradual recovery:

• Clinical validation: Three-year durability provides the durability proof that gene therapy skeptics demanded
• Label optimization: The narrowed indication, while commercially painful short-term, is actually sustainable and safer
• Market recovery potential: As safety concerns normalize and physicians gain confidence in the restricted population, volume can rebuild
• Franchise potential: Sarepta continues pipeline work on other rare diseases, though Elevidys remains the commercial engine

SRPT currently carries a Zacks Rank of #3 (Hold), reflecting this mixed outlook. For investors considering long build up strategies in beaten-down biotech names, Sarepta requires patience—but the clinical fundamentals and market opportunity are incrementally improving.

The stocks that eventually deliver returns for patient investors are often those that survive periods of skepticism. For Sarepta Therapeutics, the three-year Elevidys data suggests the worst may be behind it, making this an intriguing name for contrarian long build up portfolios to consider monitoring.